Blinatumomab for infant acute lymphoblastic leukemia
- 23 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (17), 1501-1504
- https://doi.org/10.1182/blood.2019004008
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyJournal of Clinical Oncology, 2019
- Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomabBlood, 2018
- Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALLBlood Advances, 2018
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaBlood, 2018
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2016
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticityNature Communications, 2016
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyBlood, 2016
- Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolLeukemia, 2015
- Lineage switch in childhood acute leukemia: An unusual event with poor outcomeAmerican Journal of Hematology, 2012
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trialThe Lancet, 2007